BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 11466404)

  • 1. Mutation in the class II trans-activator leading to a mild immunodeficiency.
    Wiszniewski W; Fondaneche MC; Le Deist F; Kanariou M; Selz F; Brousse N; Steimle V; Barbieri G; Alcaide-Loridan C; Charron D; Fischer A; Lisowska-Grospierre B
    J Immunol; 2001 Aug; 167(3):1787-94. PubMed ID: 11466404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conserved residues of the bare lymphocyte syndrome transcription factor RFXAP determine coordinate MHC class II expression.
    Long AB; Ferguson AM; Majumder P; Nagarajan UM; Boss JM
    Mol Immunol; 2006 Feb; 43(5):395-409. PubMed ID: 16337482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discoordinate expression of invariant chain and MHC class II genes in class II transactivator-transfected fibroblasts defective for RFX5.
    Peijnenburg A; Van Eggermond MJ; Gobin SJ; Van den Berg R; Godthelp BC; Vossen JM; Van den Elsen PJ
    J Immunol; 1999 Jul; 163(2):794-801. PubMed ID: 10395672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel mutations within the RFX-B gene and partial rescue of MHC and related genes through exogenous class II transactivator in RFX-B-deficient cells.
    Nagarajan UM; Peijnenburg A; Gobin SJ; Boss JM; van den elsen PJ
    J Immunol; 2000 Apr; 164(7):3666-74. PubMed ID: 10725724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of MHC class II gene expression in a patient with a single amino acid substitution in the class II transactivator protein CIITA.
    Quan V; Towey M; Sacks S; Kelly AP
    Immunogenetics; 1999 Oct; 49(11-12):957-63. PubMed ID: 10501838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome).
    Steimle V; Otten LA; Zufferey M; Mach B
    Cell; 1993 Oct; 75(1):135-46. PubMed ID: 8402893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency.
    Dziembowska M; Fondaneche MC; Vedrenne J; Barbieri G; Wiszniewski W; Picard C; Cant AJ; Steimle V; Charron D; Alca-Loridan C; Fischer A; Lisowska-Grospierre B
    Immunogenetics; 2002 Feb; 53(10-11):821-9. PubMed ID: 11862382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients.
    Masternak K; Barras E; Zufferey M; Conrad B; Corthals G; Aebersold R; Sanchez JC; Hochstrasser DF; Mach B; Reith W
    Nat Genet; 1998 Nov; 20(3):273-7. PubMed ID: 9806546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two newly diagnosed HLA class II-deficient patients identified by rapid vector-based complementation analysis reveal discoordinate invariant chain expression levels.
    Schmetterer KG; Seidel MG; Körmöczi U; Rottal A; Schwarz K; Matthes-Martin S; Steinberger P; Pickl WF
    Int Arch Allergy Immunol; 2010; 152(4):390-400. PubMed ID: 20197681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL).
    Cycon KA; Rimsza LM; Murphy SP
    Exp Hematol; 2009 Feb; 37(2):184-194. PubMed ID: 19081173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation of RFXAP, a regulator of MHC class II genes, in primary MHC class II deficiency.
    Villard J; Lisowska-Grospierre B; van den Elsen P; Fischer A; Reith W; Mach B
    N Engl J Med; 1997 Sep; 337(11):748-53. PubMed ID: 9287230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the defect in IFN-gamma induction of MHC class II genes in G1B cells: identification of a novel and functionally critical leucine-rich motif (62-LYLYLQL-68) in the regulatory factor X 5 transcription factor.
    Brickey WJ; Wright KL; Zhu XS; Ting JP
    J Immunol; 1999 Dec; 163(12):6622-30. PubMed ID: 10586057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency.
    Zhou H; Glimcher LH
    Immunity; 1995 May; 2(5):545-53. PubMed ID: 7749985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation.
    Masternak K; Reith W
    EMBO J; 2002 Mar; 21(6):1379-88. PubMed ID: 11889043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular analysis of an MHC class II deficiency patient reveals a novel mutation in the RFX5 gene.
    Peijnenburg A; Van Eggermond MC; Van den Berg R; Sanal O; Vossen JM; Van den Elsen PJ
    Immunogenetics; 1999 Apr; 49(4):338-45. PubMed ID: 10079298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells.
    Liu A; Takahashi M; Toba K; Zheng Z; Hashimoto S; Nikkuni K; Furukawa T; Koike T; Aizawa Y
    Hematol Oncol; 1999 Dec; 17(4):149-60. PubMed ID: 10725870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas.
    Kanaseki T; Ikeda H; Takamura Y; Toyota M; Hirohashi Y; Tokino T; Himi T; Sato N
    J Immunol; 2003 May; 170(10):4980-5. PubMed ID: 12734341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defective MHC class II expression in an MHC class II deficiency patient is caused by a novel deletion of a splice donor site in the MHC class II transactivator gene.
    Peijnenburg A; Van den Berg R; Van Eggermond MJ; Sanal O; Vossen JM; Lennon AM; Alcaïde-Loridan C; Van den Elsen PJ
    Immunogenetics; 2000 Jan; 51(1):42-9. PubMed ID: 10663561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An isotype-specific activator of major histocompatibility complex (MHC) class II genes that is independent of class II transactivator.
    Douhan J; Lieberson R; Knoll JH; Zhou H; Glimcher LH
    J Exp Med; 1997 Jun; 185(11):1885-95. PubMed ID: 9166418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction.
    Chin KC; Mao C; Skinner C; Riley JL; Wright KL; Moreno CS; Stark GR; Boss JM; Ting JP
    Immunity; 1994 Nov; 1(8):687-97. PubMed ID: 7600294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.